Name: Novo CEO Says Volumes to Compensate for Price Decreases
Uploaded: 2026-02-04T21:40:47+00:00
Duration: 389 s

Speakers

Mike Doustdar — CEO, Novo Nordisk

Summary

Novo Nordisk CEO Mike Doustdar discusses the company's response to investor concerns after its shares plunged on US GLP-1 price cuts. He argues that lower prices are necessary to expand the market and that volume growth—supported by the Wegovy pill launch, a deep pipeline including Cagrisema, and Novo's manufacturing and commercial scale—will compensate for the pricing headwind, which he expects to hit in 2026. He also says Novo has no plans for mass layoffs and is adjusting headcount as the business evolves.

Novo Nordisk shares fell amid GLP-1 pricing pressure.
CEO says price cuts aim to expand affordability and market size.
Early Wegovy pill uptake is strong: 170,000 patients in four weeks.
Wegovy pill is mostly reaching new patients at low doses, with limited cannibalization.
GLP-1 market remains underpenetrated with about 2 billion affected and 20 million treated.
US repricing is expected to create a 2026 headwind for Novo.
Novo expects Cagrisema approval later this year and launch early next year.
Company rules out mass layoffs and cites pipeline, manufacturing, and commercial strengths.

Ideas

Mike Doustdar CEO, Novo Nordisk 0:44

Volumes will offset GLP-1 price cuts.

Doustdar argues that US GLP-1 price cuts—especially for Wegovy and Ozempic—are a deliberate move to expand affordability and the overall market, and that volume growth will compensate. He points to a deeply underpenetrated diabetes/obesity market, strong early Wegovy pill uptake (170,000 patients in four weeks, mostly new patients at the lowest dose, with efficacy similar to injectable), a pipeline including Cagrisema (filed for approval, launch expected early next year as the first Amylin combination with highest efficacy), and Novo's focused pipeline, manufacturing scale, and commercial capabilities. He acknowledges the US repricing will create a 2026 headwind, especially since the US is 55% of sales, but expects volumes to more than offset it over time.

Mike Doustdar CEO, Novo Nordisk 1:47

GLP-1 market underpenetrated and growing.

The GLP-1 diabetes/obesity market is growing and remains vastly underpenetrated: close to 2 billion people have diabetes, obesity, or overweight, while Novo and its competitor together treat only about 20 million. Doustdar expects lower prices to improve affordability and expand the market, driving volume growth for participants.

This Bloomberg Markets video, published February 04, 2026, features Mike Doustdar discussing NVO, OZEM. 2 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Mike Doustdar · Tickers: NVO, OZEM

Novo CEO Says Volumes to Compensate for Price Decreases

Summary

Ideas

Up Next